Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-SAVE: extended-interval osimertinib dosing in EGFR-mutated advanced non-small cell lung cancer
NL-OMON59062Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59062.